Filing Summary
Registrant: Adagio Therapeutics, Inc. (now Invivyd, Inc.), a Delaware biotechnology company trading as ADGI on Nasdaq. Report date: December 14, 2021. The filing is a Form 8-K under Item 7.01, Regulation FD Disclosure.
Business Context and Reporting Period
The filing reports the issuance of a press release concerning ADG20, the company’s investigational SARS-CoV-2 antibody, and its activity against the Omicron variant. This is not a periodic financial report and does not provide results for a fiscal quarter or year.
Key Financial and Operating Metrics
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
- The filing text does not provide a clear quantitative value for ADG20’s reduction in in vitro neutralizing activity against Omicron; the referenced press release is identified as Exhibit 99.1 but its substantive text is not included in the provided filing content.
Material Changes, Outlook, and Risks
- The principal disclosed development is reduced in vitro neutralizing activity of ADG20 against the Omicron SARS-CoV-2 variant.
- This finding may affect the program’s potential clinical and commercial prospects, but the provided filing does not state specific changes to development plans, regulatory strategy, guidance, timelines, or financial outlook.
- In vitro results may not directly predict clinical efficacy; the filing text does not provide clinical outcome data or management’s detailed interpretation.
- The disclosure was furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.
Investor Verification Items
- Review Exhibit 99.1 for the magnitude and testing methodology of the reduction in neutralizing activity.
- Verify whether the company changed ADG20’s clinical, regulatory, manufacturing, or commercialization plans following the Omicron data.
- Assess subsequent filings for updated efficacy, safety, regulatory, financing, liquidity, and program-prioritization information.
- Confirm the company’s current legal name and ticker, as this filing identifies the registrant as Adagio Therapeutics, Inc., while the request identifies Invivyd, Inc.